Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,661 across all filing types
Latest filing 2020-11-25 Regulatory Filings
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to stock exchanges (National Stock Exchange of India Ltd. and Bombay Stock Exchange Limited) regarding the loss of share certificates by shareholders and the request for issuance of duplicate share certificates. It references Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to reporting such events. The content is about notifying the stock exchanges of lost share certificates and related administrative details. There is no financial data, no discussion of financial results, no management commentary, no voting results, no legal proceedings, no capital changes, and no report publication. The document is essentially a regulatory notification about share certificate loss, which fits best under Regulatory Filings (RNS) as it is a compliance-related announcement that does not fit other specific categories.
2020-11-25 English
Morepen Laboratories Ltd has informed BSE regarding loss of share Certificates of the Company
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to stock exchanges (National Stock Exchange of India Ltd. and Bombay Stock Exchange Limited) regarding the loss of share certificates by certain shareholders and the request for issuance of duplicate share certificates. It references Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to reporting lost share certificates. The content is about notifying the stock exchanges of these losses and related administrative actions. There is no financial data, no discussion of financial results, no management commentary, no voting results, no capital changes, or any other report type content. The document is essentially a regulatory notification about share certificate loss incidents. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-11-25 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (National Stock Exchange of India Ltd. and BSE Limited) regarding the issuance of duplicate share certificates. It references compliance with Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The content is about notifying the exchanges about the issuance of duplicate share certificates to shareholders. There is no financial data, no report attached or referenced, no management discussion, no earnings information, no voting results, no capital changes, or other report types. This is a regulatory announcement related to share certificate issuance, which does not fit into financial reports or other specific categories. It is a regulatory filing notifying the stock exchanges of a corporate action related to share certificates. Therefore, the best fitting category is Regulatory Filings (RNS). The document length is short (2352 characters), and it is a formal notification letter, not a report or announcement of a report publication.
2020-11-18 English
Morepen Laboratories Ltd has informed BSE regarding Issuance of Duplicate share Certificates by the Company
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (NSE and BSE) regarding the issuance of duplicate share certificates. It references compliance with SEBI regulations and includes details of share certificates issued as duplicates. There is no financial data, earnings information, or report content. The document is an official notification about share certificate issuance, which relates to shareholding records but does not constitute a financial report or capital change announcement like a share issue or buyback. It is a regulatory announcement informing the exchanges about administrative action on share certificates. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2020-11-18 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is a detailed transcript of an investors and analyst conference call discussing the financial results for the second quarter (Q2) of fiscal year 2020-2021. It includes management commentary on revenue, segment performance, export markets, patents, and expansion plans. The presence of a moderator, management speakers, and Q&A format typical of earnings calls is evident. The document references unaudited standalone and consolidated financial results for the quarter and half year ended 30th September 2020. This matches the characteristics of a Call Transcript (CT) filing type, which is a full text transcript of company conference calls such as earnings calls with Q&A. The document is about 15,000 characters long, contains substantive discussion of financial results and business outlook, and is not merely an announcement or summary. Therefore, the appropriate classification is CT with high confidence.
2020-11-17 English
Please find attached transcript of Investors and Analyst Conference Call organized on Tuesday, 10th November, 2020 at 12.00 Noon (IST) subsequent to declaration of unaudited standalone ....
Call Transcript Classification · 100% confidence The document is a detailed transcript of an investors and analyst conference call discussing the financial results for the second quarter (Q2) of fiscal year 2020-2021. It includes management commentary on revenue, segment performance, export markets, patents, and expansion plans. The presence of a moderator, management speakers, and Q&A format typical of earnings calls is evident. The document explicitly states it is a transcript of the Q2 FY21 earnings conference call. Therefore, this document fits the category of a Call Transcript (CT). The document length (15,000 characters) and detailed content confirm it is the full transcript, not just an announcement or summary.
2020-11-17 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.